PMID- 19466878
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20090624
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 18
IP  - 7
DP  - 2009 Jul
TI  - Novel investigational drugs for gastric cancer.
PG  - 945-55
LID - 10.1517/13543780902969455 [doi]
AB  - BACKGROUND: Gastric cancer still represents a leading cause of death worldwide. 
      Several cytotoxic agents have demonstrated activity and combination regimens 
      improve progression-free survival, overall survival and quality of life. 
      Nevertheless, now there is no standard therapy for advanced gastric cancer 
      patients. OBJECTIVE: To evaluate the role of new investigational agents. METHODS: 
      We analysed Phase I, II and III studies that evaluated tailored drugs directed 
      against the epidermal growth factor receptor (EGFR), the c-erbB2, the vascular 
      endothelial growth factor (VEGF), the vascular endothelial growth factor receptor 
      (VEGFR), the matrix metalloproteinases (MMP) and the mammalian target of 
      rapamycin (mTOR). CONCLUSION: Data from Phase II trials indicate the potential of 
      improved efficacy of chemotherapy when administered in combination with 
      bevacizumab and cetuximab. Trastuzumab results are ongoing, while marimastat has 
      not obtained clinical developments even if it has demonstrated to be an active 
      drug in this setting of patients.
FAU - Vecchione, Loredana
AU  - Vecchione L
AD  - Second University of Naples, School of Medicine, Division of Medical Oncology 'F. 
      Magrassi & A. Lanzara', Department of Clinical and Experimental Medicine and 
      Surgery, c/o II Policlinico Via S. Pansini 5, 80131 Naples, Italy.
FAU - Orditura, Michele
AU  - Orditura M
FAU - Ciardiello, Fortunato
AU  - Ciardiello F
FAU - De Vita, Ferdinando
AU  - De Vita F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/metabolism/*therapeutic use
MH  - Clinical Trials, Phase II as Topic/methods/mortality
MH  - Drugs, Investigational/chemistry/metabolism/*therapeutic use
MH  - Humans
MH  - Stomach Neoplasms/*drug therapy/metabolism/mortality
RF  - 82
EDAT- 2009/05/27 09:00
MHDA- 2010/03/05 06:00
CRDT- 2009/05/27 09:00
PHST- 2009/05/27 09:00 [entrez]
PHST- 2009/05/27 09:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
AID - 10.1517/13543780902969455 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2009 Jul;18(7):945-55. doi: 
      10.1517/13543780902969455.